Table 2.
Maximum Severity of Adverse Events (n = 44). All Grades 1–4 Adverse Events Observed in This Trial are Showna,b
| Grade 1 | Grade 2 | |||||
|---|---|---|---|---|---|---|
| Arm 1 (n = 14) | Arm 2 (n = 15) | Arm 3 (n = 15) | Arm 1 (n = 14) | Arm 2 (n = 15) | Arm 3 (n = 15) | |
| Constitutional | ||||||
| Flu-like symptoms | 2 | 1 | 1 | |||
| Anorexia | 1 | |||||
| Fatigue | 1 | 1 | 9 | |||
| Nausea | 3 | |||||
| Infection | 1 | 1 | ||||
| Musculoskeletal | ||||||
| Myalgia | 4 | 1 | 4 | 1 | ||
| Arthralgia | 1 | 8 | 1 | |||
| Bone pain | 1 | 1 | 1 | 1 | ||
| Hand edema | 1 | |||||
| Pain NOS | 1 | 1 | ||||
| Neurologic | ||||||
| Mood alteration | 1 | 1 | ||||
| Insomnia | 1 | |||||
| Genitourinary: urinary frequency | 1 | |||||
Abbreviation: NOS = not otherwise specified.
a
The numbers represent the number of patients within each arm who experienced a particular event at any point during the treatment period, with the highest grade reported for any single individual.
b
Adverse event grade is according to National Cancer Institute Common Terminology Criteria version 2.0.